Pharmaceutical Industry discussion, review, analysis, news and information.

Researchers have come up with bioengineered bird flu antibodies, producing what they refer to as "humanized monoclonal" antibodies. Complete protection from the H5N1 bird flu strain has been confered by one of the two engineered antibodies developed.

"We have shown here the proof of principle that passive antibody therapy can be an effective tool for both prophylaxis against and treatment of highly pathogenic H5N1 influenza virus, providing the immediate immunity needed, which combined with social distancing could limit the transmission of H5N1 to others and contain a future influenza pandemic," the researchers said.

Critics say, however, that as the studies were made on mice, further clinical trials will have to be made before it can be concluded that these antibodies will work in humans. Also, humanized antibodies are limited in that it recognizes only a small portion of the virus, and might not be effective if the virus mutates.

Read the full report from Health Day.